Mean follow-up was 64 months (16-158). Follow-up was at least of 1 year in all patients, 2 years in 96% of patients, 3 years in 86.7% and 4 years in 68% of patients. FibroTest was applicable in 74/75 patients (98.6%) and FibroScan in 68/75 patients (90.7%). Three patients (4%) declared an excessive alcohol consumption, whereas 27 (36%) had a CDT>1.8%. Overall, 36% of patients developed significant fibrosis (F>2). Independent factors associated with the development of significant fibrosis were weight at evaluation (p=0.003), cold ischemia (p=0.05), learn more and alcohol abuse (p=0.04), but not the development of metabolic syndrome after LT. Conclusion

Alcohol consumption is underestimated after LT for pure alcoholic cirrhosis and should be evaluated with objective biomarkers such as CDT. Abusive drinking after LT is associated with significant progression of fibrosis that should be regularly assessed with noninvasive methods. Disclosures: Marika Rudler – Speaking and Teaching: Gilead Pascal Lebray – Grant/Research Support: Merck, astellas; Speaking and Teaching: Janssen, MSD, Gilead

Thierry Poynard – Advisory Committees Forskolin mw or Review Panels: Merck; Grant/Research Support: BMS, Gilead; Stock Shareholder: Biopredictive The following people have nothing to disclose: Geraldine Rousseau, Corinne Vezinet, Daniel Eyraud, Jean-Christophe Vaillant, Dominique Thabut Background: Immune response failure during HCV infection has been associated with the activity of regulatory T cells. Hepatitis C-related cirrhosis is the one of the main indication for liver transplantation (LT). However, 80% of transplanted patients present an accelerated recurrence of the disease. This study aim was to assess regulatory T-cell subsets, and T helper 1, 2 and 17 cells involvement in recurrent hepatitis C after liver transplantation. Patients and Methods: Peripheral blood mononuclear cells, obtained before and one month after

LT, from 22 liver transplant recipients have been analysed. Forty four key molecules, related to Treg, T helper 1, 2 and 17 responses, were evaluated by using qRT-PCR analysis. Liver transplant recipients have been classified on two groups in function of fibrosis evaluation observed on the one year follow-up biopsy. The severity 上海皓元 of hepatitis C recurrence was evaluated by the results METAVIR analysis on one year liver biopsy (mild: F<1, severe F≥ 1). The results of patients that will develop a severe hepatitis C recurrence (n=9) were compared to those obtained in patients will develop a mild recurrence (n=13). Results: Our results demonstrated a significant increase in mRNA levels of Treg markers (CD4,CD25,TGFf>,CTLA-4, GATA-3, and IL-10Ra/p) early after liver transplantation (one month) in patients with a severe evolution of HCV recurrence. Th1 markers (IL-2, IFNg, IL-23, T-bet), which could be implicated in antiviral response, were also elevated in same group of patients.